GMP and cGMP for pharmaceuticals: the FDA, EU and MHRA requirements
Good manufacturing practice (GMP) is the set of rules a medicines maker follows so that it makes, imports and checks every batch to the quality its intended use requires. It is law in the US, the EU and the UK. The FDA calls it current good manufacturing practice (cGMP) and sets the minimum in 21 CFR Parts 210 and 211; a drug made in breach of them counts as adulterated. In the EU, Article 46(f) of Directive 2001/83/EC requires every holder of a manufacturing authorisation to follow the GMP principles and guidelines that Directive (EU) 2017/1572 lays down, and makers must take the EU GMP guidelines into account when they apply them. In the UK, the Human Medicines Regulations 2012 bind every holder of a manufacturer’s licence (regulations 37 and 38).
Meeting GMP is also part of selling a medicine in each market: the US agency reviews cGMP compliance when it approves a new or generic drug, and its mutual recognition agreements with the EU and the UK let inspectors rely on each other’s inspections.
GMP in the US, the EU and the UK: the main points in brief
- In all three markets, GMP asks for the same core work: written procedures, trained staff, controlled premises and equipment, tested materials, validated processes, investigated deviations, batch records, complaint handling, recalls and retained samples.
- cGMP is the FDA’s name for it, and the C stands for current.
- In the US, a quality control unit approves or rejects each batch. In the EU and the UK, a qualified person is also responsible for each batch before it goes on sale.
Where GMP is law: each market’s duty, quoted
The US: 21 CFR Parts 210 and 211
The failure to comply with any regulation set forth in this part and in parts 211, 213, 225, and 226 of this chapter in the manufacture, processing, packing, or holding of a drug shall render such drug to be adulterated under section 501(a)(2)(B) of the act and such drug, as well as the person who is responsible for the failure to comply, shall be subject to regulatory action.
In plain words. A drug made, processed, packed or held in breach of the cGMP rules counts as adulterated, and the agency can act against the drug and against the person responsible.
The Act says current good manufacturing practice includes “managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products” (21 U.S.C. 351).
The EU: Directive (EU) 2017/1572 and Directive 2001/83/EC
The Member States shall ensure that the manufacturing operations are carried out by manufacturers in accordance with good manufacturing practice and with the manufacturing authorisation. This provision shall also apply to medicinal products intended only for export.
In plain words. Every manufacturer follows GMP and its manufacturing authorisation, for products made only for export too.
Directive 2001/83/EC puts the duty on the authorisation holder itself (Article 46(f)). Article 3(2) of Directive (EU) 2017/1572 tells makers and authorities to “take into account the detailed guidelines referred to in the second paragraph of Article 47 of Directive 2001/83/EC”, which the European Commission publishes as EudraLex Volume 4.
The UK: the Human Medicines Regulations 2012
The licence holder must comply with the principles and guidelines for good manufacturing practice set out in the Good Manufacturing Practice Directive which apply under or by virtue of regulation B17.
In plain words. Great Britain follows the EU’s GMP directive and guidelines as they stood at 11pm on 31 December 2020, with UK names in place of EU ones, until UK ministers or the licensing authority replace or amend them (regulations 8(1), B17(3) and C17(3)).
In law, the Good Manufacturing Practice Directive for Great Britain is Directive 2003/94/EC as Schedule 2A modifies it, or regulations made under regulation B17 once in force (regulation 8(1)). Regulation C17(3) keeps the EU guidelines “as they applied immediately before IP completion day” unless the licensing authority replaces or amends them; for Annex 1, see “Sterile products” below. For Northern Ireland, the definition points to Directive 2003/94/EC without the Great Britain modifications.
Who must follow GMP
- Drug makers in the US, and firms that do part of the work. Part 211 covers drug products, which 210.3(b)(4) defines as “a finished dosage form, for example, tablet, capsule, solution, etc., that contains an active drug ingredient generally, but not necessarily, in association with inactive ingredients”. A firm that carries out only some operations “need only comply with those regulations applicable to the operations in which the person is engaged” (210.2(b)).
- Active ingredient makers. The Act’s definition of a drug includes “articles intended for use as a component of any article specified in clause (A), (B), or (C)” (21 U.S.C. 321(g)(1)(D)), so its cGMP duty covers active ingredients too. The FDA’s guidance for them is ICH Q7, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. In the EU, Part II of the guidelines covers them, and EU and UK medicine makers may use only active substances made to GMP (Article 46(f); regulation 37(3)).
- Biologics and cell and tissue products. Parts 600 to 680 and Part 1271 add to Parts 210 and 211, and where they conflict, the regulation specific to the product applies (210.2(a)).
- Drugs for early trials. A drug for a phase 1 study is exempt from Part 211 until it becomes available for use in a phase 2 or phase 3 study, or goes on lawful sale (210.2(c)). The statute’s cGMP still applies to it.
- Medical gases. Since 18 December 2025, medical gases as 213.3(b)(12) defines them follow Part 213 (211.1(a)).
- Medical devices. Devices follow their own cGMP rule, 21 CFR Part 820, the quality management system regulation (QMSR). Our guide to ISO 13485 and the QMSR covers it.
- EU authorisation holders. Directive (EU) 2017/1572 applies to every holder of a manufacturing authorisation (Article 2(1)), which covers manufacture, including for export, and imports from outside the EU (Directive 2001/83/EC, Article 40(1) and (3)). Investigational medicinal products follow Commission Delegated Regulation (EU) 2017/1569.
- UK licence holders. A person needs a manufacturer’s licence to manufacture or assemble a medicinal product, or to import one into Great Britain from a country other than Northern Ireland or an approved country for import (regulation 17(1)). Regulation 36(1) makes regulations 37 to 41 provisions of that licence.
What to do. List the operations you carry out (manufacture, processing, packing, holding, testing, import, batch release), the products they cover and the markets you supply. Name the law that applies to each, and the authorisation or licence that covers it.
Evidence to keep. A scope statement that names each operation, product and market with its authorisation or licence; for EU and UK sites, the site master file, “A document describing the GMP related activities of the manufacturer” (EU GMP guidelines, Chapter 4).
Where GMP inspections find the most problems, and what to fix first
The FDA publishes, for each fiscal year, the regulations its investigators cited on Form FDA 483, the list of observations they hand a firm at the end of an inspection. In fiscal year 2025 (inspections that ended between 1 October 2024 and 30 September 2025), 713 of the 483s in its data set cited drug requirements. These are the Part 211 paragraphs cited most often:
| Paragraph | What it requires, in plain words | Times cited, fiscal year 2025 |
|---|---|---|
| 211.22(d) | Written quality control unit responsibilities and procedures, followed | 243 |
| 211.192 | A written investigation of every unexplained discrepancy and failed batch | 236 |
| 211.100(a) | Written, approved procedures for production and process control | 169 |
| 211.160(b) | Scientifically sound specifications, standards, sampling plans and test procedures | 121 |
| 211.68(b) | Controls over computer systems and the records in them | 110 |
| 211.113(b) | Procedures, with validation, that keep sterile products free of microbial contamination | 105 |
| 211.67(a) | Equipment cleaned and maintained at appropriate intervals | 95 |
| 211.84(d)(2) | Components tested against their specifications, or a supplier’s results checked before you rely on them | 90 |
The table counts by the reference number the FDA gives each citation, so a sub-paragraph such as 211.67(b)(3) counts on its own. The agency says these spreadsheets “are not a comprehensive listing of all inspectional observations”, because investigators prepare some 483s by hand.
The MHRA’s latest published deficiency data, for 2019, list 5,292 deficiencies from its GMP inspections. Inspectors cited Chapter 1, point 1.4(xiv), on root cause analysis and corrective and preventive action after deviations, most often (210 times). Next came point 1.8(vii), on recording and investigating significant deviations (111), then Chapter 4’s point 4.8, on making records at the time of each action, and point 4.3, on approving, signing and dating instructions (103 each).
What to do. Check these points first: the quality unit’s written procedures, investigations with their root cause and corrective action, written production procedures, laboratory controls and computer controls.
What 21 CFR Part 211 requires, subpart by subpart, with what to do and the evidence to keep
Subparts B to K set the requirements below. Most subparts require records; Subpart J sets the content of the main records and how long to keep them.
B. Organization and personnel: the quality control unit and trained staff
There shall be a quality control unit that shall have the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products, and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated.
In plain words. One named unit decides whether the firm may use each material, label and batch, and checks that the production records show no errors, or that the firm fully investigated any it found.
The unit also approves or rejects every procedure or specification that affects the drug’s quality (211.22(c)), and its responsibilities and procedures must be in writing (211.22(d)). cGMP training “shall be conducted by qualified individuals on a continuing basis” (211.25(a)).
What to do. Name the quality control unit and write down its responsibilities and authority. Train each person in their operations and in cGMP, and repeat the training.
Evidence to keep. The unit’s written responsibilities and procedures; training records for each person; the name, address and qualifications of each consultant (211.34).
C. Buildings and facilities: space and layout that prevent mix-ups and contamination
Any such building shall have adequate space for the orderly placement of equipment and materials to prevent mixups between different components, drug product containers, closures, labeling, in-process materials, or drug products, and to prevent contamination.
In plain words. The building has the room and the layout to keep materials and products apart and free of contamination.
Section 211.42(c) lists the operations that need separate or defined areas, from receipt and quarantine to aseptic processing, which needs, as appropriate, easily cleaned floors, walls and ceilings, air filtered through high-efficiency particulate air (HEPA) filters under positive pressure, and environmental monitoring. Penicillin has its own facilities (211.42(d)).
What to do. Map each operation in 211.42(c) to a defined area on your site plan, and write the sanitation, cleaning and pest control procedures.
Evidence to keep. The site plan with its defined areas and material flows; sanitation and pest control procedures; environmental monitoring records for aseptic areas.
D. Equipment: design, cleaning, calibration and computer controls
Equipment and utensils shall be cleaned, maintained, and, as appropriate for the nature of the drug, sanitized and/or sterilized at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements.
In plain words. The firm cleans, maintains and, where needed, sterilises its equipment often enough to prevent breakdowns and contamination.
Written procedures set who cleans and maintains each item, when and how (211.67(b)). The firm calibrates or checks automatic and electronic equipment, computers included, under a written programme, and controls who can change records in a computer system (211.68). Electronic records that Part 211 requires also fall under 21 CFR Part 11 (11.1(b)). Our guide to Part 11 and Annex 11 covers them.
What to do. Write a cleaning procedure for each piece of equipment, keep a log for each major item, run a calibration programme, and control who can change computer records.
Evidence to keep. Equipment cleaning and use logs (211.182); calibration records; access and backup records for computer systems.
E. Components, containers and closures: quarantine and testing before use
Each lot of components, drug product containers, and closures shall be withheld from use until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit.
In plain words. No lot of components, containers or closures goes into production until the firm has sampled, tested or examined it, as appropriate, and the quality control unit has released it.
Each lot gets a code and a status: quarantined, approved or rejected (211.80(d)). At least one test verifies each component’s identity, and a supplier’s report of analysis can replace the other tests only if the maker validates the supplier’s results at appropriate intervals (211.84(d)).
What to do. Write the receipt, sampling and testing procedures, run an identity test on every lot of every component, and check the results of each supplier whose report you rely on at set intervals.
Evidence to keep. Component, container, closure and labelling records with each lot’s tests and disposition (211.184); the supplier checks behind each report you accept.
F. Production and process controls: written procedures, checked steps and validated processes
Written production and process control procedures shall be followed in the execution of the various production and process control functions and shall be documented at the time of performance. Any deviation from the written procedures shall be recorded and justified.
In plain words. Staff follow the written production procedures, record each step as they do it, and justify any departure.
The quality control unit approves these procedures and every change to them (211.100(a)). A second person checks each component weighed out and added to the batch; with automated equipment, one person verifies (211.101). For sterile products, the procedures “shall include validation of all aseptic and sterilization processes” (211.113(b)).
What to do. Write the production procedures and send them, and every change to them, to the quality control unit for approval. Record each deviation with its justification at the time it happens.
Evidence to keep. Approved production procedures; batch records with the second-person checks, yields and in-process results; deviation records; validation reports for aseptic and sterilisation processes.
G. Packaging and labelling control: the right label on every container
There shall be written procedures designed to assure that correct labels, labeling, and packaging materials are used for drug products; such written procedures shall be followed.
In plain words. Written procedures make sure each product gets the right labels and packaging.
The firm stores the labels for each product and strength apart (211.122(d)), reconciles the labelling issued, used and returned (211.125(c)), and inspects the lines immediately before use (211.130(e)). Each product carries an expiration date that stability testing supports (211.137(a)), and most over-the-counter products for retail sale need tamper-evident packaging (211.132).
What to do. Write the label control, reconciliation and line clearance procedures, and set each product’s expiration date from its stability data.
Evidence to keep. Records of each labelling shipment and its examination (211.122(c)); reconciliation records; line clearance results in the batch record; the stability data behind each expiration date.
H. Holding and distribution: storage conditions and records that make a recall possible
Written procedures shall be established, and followed, describing the distribution of drug products. They shall include:
- (a) A procedure whereby the oldest approved stock of a drug product is distributed first. Deviation from this requirement is permitted if such deviation is temporary and appropriate.
- (b) A system by which the distribution of each lot of drug product can be readily determined to facilitate its recall if necessary.
In plain words. As a rule, the firm ships its oldest approved stock first, and it knows where every lot went, so it can recall one.
Warehousing procedures hold products in quarantine until the quality control unit releases them, and store them in the right conditions (211.142).
What to do. Write the warehousing and distribution procedures, and test that you can trace every lot to its consignees.
Evidence to keep. Storage condition records; distribution records (211.196).
I. Laboratory controls: specifications, release testing, stability and reserve samples
For each batch of drug product, there shall be appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release.
In plain words. The laboratory tests every batch against its final specification, including the identity and strength of each active ingredient, before release.
Specifications, standards, sampling plans and test procedures must be scientifically sound (211.160(b)), the firm establishes and documents the accuracy and reliability of its test methods (211.165(e)), and a written stability programme sets expiration dates (211.166(a)). Reserve samples hold at least twice the quantity the required tests need, other than sterility and pyrogen tests. The firm keeps them for 1 year after the expiration date of the drug product (for an active ingredient, of the last lot of drug product that contains it), with shorter periods for radioactive drugs and 3 years after distribution for over-the-counter products exempt from expiration dating (211.170(a) and (b)).
What to do. Write a specification and a validated test method for every material and product, test every batch before release, run the stability programme and keep reserve samples.
Evidence to keep. Laboratory records with complete data, calculations and a second person’s review (211.194); method validation; stability data; the reserve sample log and the yearly visual examinations (211.170(b)).
J. Records and reports: what to keep, for how long, and the yearly product review
Any unexplained discrepancy (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records) or the failure of a batch or any of its components to meet any of its specifications shall be thoroughly investigated, whether or not the batch has already been distributed.
In plain words. The firm investigates every unexplained discrepancy or failed specification, including in batches already shipped.
The firm keeps each batch’s records for at least 1 year after the batch’s expiration date, or 3 years after distribution for over-the-counter products exempt from expiration dating (211.180(a)). At least once a year it reviews each product’s quality standards, using its batches, complaints, recalls, returns and investigations (211.180(e)), and it tells its responsible officials in writing about recalls, inspection observations and regulatory actions (211.180(f)). Each complaint record holds the investigation’s findings or the reason the firm did not investigate (211.198).
What to do. Set a retention schedule, run the yearly product review, investigate every discrepancy or failure, and send each investigation, recall and inspection finding to the firm’s responsible officials.
Evidence to keep. Master and batch records; investigation reports with conclusions and follow-up; the yearly review for each product; complaint files.
K. Returned and salvaged drug products
Returned drug products shall be identified as such and held.
In plain words. The firm marks returned products as returned and holds them until it decides what to do with them.
If the way someone held or shipped a returned product casts doubt on its quality, the firm destroys it unless tests prove it meets its standards (211.204). Products exposed to improper storage in natural disasters, fires, accidents or equipment failures “shall not be salvaged and returned to the marketplace” (211.208).
What to do. Write a procedure for holding, testing and deciding on returns, and investigate other batches when a return points to them.
Evidence to keep. A record of each return with the product, lot, reason, quantity, date and disposition (211.204); salvage records (211.208).
What the EU GMP rules require, article by article, with what to do and the evidence to keep
Directive (EU) 2017/1572 sets each principle in an article, and Part I of the EU GMP guidelines covers the same subject in a chapter.
Pharmaceutical quality system (Article 6, Chapter 1)
The Member States shall ensure that the manufacturers establish, implement and maintain an effective pharmaceutical quality system, involving the active participation of the senior management and the personnel of the different departments.
In plain words. The maker runs a quality system that its senior management and every department take part in.
Chapter 1 gives senior management “the ultimate responsibility to ensure an effective Pharmaceutical Quality System is in place” (1.5), and asks for management review, a quality manual and a product quality review of every product, normally each year (1.6, 1.7 and 1.10).
What to do. Write the quality manual, hold management reviews, and complete a product quality review for each product every year.
Evidence to keep. The quality manual; management review records; the yearly product quality reviews.
Personnel and the qualified person (Article 7, Chapter 2)
The duties of the managerial and supervisory staff, including the qualified persons referred to in Article 48 of Directive 2001/83/EC, responsible for implementing and operating good manufacturing practice, shall be defined in job descriptions. Their hierarchical relationships shall be defined in an organisation chart.
In plain words. The maker writes down the duties of each manager and qualified person and shows on an organisation chart who reports to whom.
The maker verifies that its training works (Article 7(4)). The authorisation holder has “permanently and continuously at his disposal the services of at least one qualified person” (Directive 2001/83/EC, Article 48(1)), who certifies each production batch in a register kept for at least five years (Article 51(3)).
What to do. Write a job description for each key post, keep an organisation chart that shows the qualified person, and record how you check that training works.
Evidence to keep. Job descriptions; the organisation chart; training records with the check of effectiveness; the qualified person’s register of certified batches.
Premises and equipment (Article 8, Chapter 3)
Premises and equipment to be used for manufacturing or import operations, which are critical to the quality of the products, shall be subjected to appropriate qualification and validation.
In plain words. The maker proves that the premises and equipment that matter for quality work as intended.
Article 8(2) asks for premises and equipment laid out, designed and operated “to minimise the risk of error and to permit effective cleaning and maintenance”. Annex 15 of the guidelines covers qualification and validation.
What to do. Qualify each critical room, utility and piece of equipment before you use it.
Evidence to keep. Qualification protocols and reports; cleaning and maintenance records.
Documentation and data integrity (Article 9, Chapter 4)
The documentation system shall ensure data quality and integrity. Documents shall be clear, free from error and kept up to date.
In plain words. The maker’s documents are clear, correct and current, and their data are accurate and complete.
The maker keeps each batch’s documentation “for at least 1 year after the expiry date of the batches to which it relates or at least 5 years after the certification referred to in Article 51(3) of Directive 2001/83/EC, whichever is the longer period” (Article 9(1)). It validates any electronic system before it replaces paper, and keeps audit trails (Article 9(2)). Annex 11 of the guidelines covers computerised systems.
What to do. Keep each batch’s documents for the longer of the two periods, and validate every electronic system that holds GMP records before you use it.
Evidence to keep. The site master file; specifications, instructions, procedures and batch records; validation records and audit trails for electronic systems.
Production (Article 10, Chapter 5)
All process deviations and product defects shall be documented and thoroughly investigated.
In plain words. The maker records and investigates every process deviation and product defect.
Makers take measures against cross contamination and mix-ups (Article 10(2)), validate each new process and each important change, and revalidate critical phases regularly (Article 10(3)).
What to do. Validate each new process and each important change, revalidate critical phases on a schedule, and investigate every deviation and defect.
Evidence to keep. Process validation reports; the revalidation schedule; deviation and defect investigations.
Sterile products: what Annex 1 requires
A Contamination Control Strategy (CCS) should be implemented across the facility in order to define all critical control points and assess the effectiveness of all the controls (design, procedural, technical and organisational) and monitoring measures employed to manage risks to medicinal product quality and safety.
In plain words. A sterile site puts in place, across the whole facility, a strategy that names every critical control point and checks that each control and monitoring measure works, to protect product quality and safety.
Annex 1 sets four grades of cleanroom (4.4): grade A for high-risk operations such as aseptic filling, grade B as its background, and grades C and D for less critical stages. The site’s environmental and process monitoring programme “forms part of the overall CCS” (9.1). For aseptic process simulation, also called a media fill, “Normally, APS (periodic revalidation) should be repeated twice a year (approximately every six months) for each aseptic process, each filling line and each shift.” (9.38).
The MHRA’s GMP guidance does not say in terms which version of Annex 1 applies at a GB site. Its guidance on GMP for clinical trials says it “remains committed to and aligned with the internationally harmonised standards of Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the EU”. Its inspectorate’s blog of 16 November 2026 says of the 2022 revision: “Since its publication, industry and regulators have been applying those requirements across a wide range of facilities, technologies, and manufacturing processes.” For a written answer for your site, ask the MHRA’s GMP inspectorate.
What to do. Write a contamination control strategy that covers every critical control point, classify and monitor each cleanroom grade, and run aseptic process simulations twice a year for each process, line and shift.
Evidence to keep. The contamination control strategy; cleanroom classification and monitoring records; aseptic process simulation reports.
Quality control and samples (Article 11, Chapter 6)
The manufacturer shall be obliged to establish and maintain a quality control system placed under the authority of a person who has the requisite qualifications and is independent of production.
In plain words. A person with the right qualifications, who is independent of production, runs quality control.
Before release, quality control takes into account the production conditions, in-process results and manufacturing documents as well as the test results (Article 11(3)). The maker keeps samples of each finished batch for at least 1 year after expiry, and of starting materials other than solvents, gases or water for at least 2 years after release, or less if the material’s stability period is shorter (Article 11(4)).
What to do. Put quality control under a qualified head who is independent of production, and keep finished product and starting material samples for the set periods.
Evidence to keep. The organisation chart that shows that independence; test and release records; the sample store and its log.
Outsourced operations (Article 12, Chapter 7)
The Member States shall require that any manufacturing or import operation or operation linked thereto which is outsourced is the subject of a written contract.
In plain words. Every piece of work the maker outsources has a written contract behind it.
The contract sets each party’s responsibilities and how the qualified person certifies each batch (Article 12(2)), and the contract acceptor may not subcontract without written authorisation (Article 12(3)). Chapter 7 makes the contract giver assess “the legality, suitability and the competence of the Contract Acceptor” before it outsources (7.5).
What to do. Assess each contract acceptor before you outsource, and put every outsourced GMP activity, contract testing included, under a written contract that says who does what.
Evidence to keep. Signed contracts; the assessment of each contract acceptor; audit reports.
Complaints and recalls (Article 13, Chapter 8)
Any complaint concerning a defect shall be recorded and investigated by the manufacturer. The manufacturer shall be required to inform the competent authority and, if applicable, the marketing authorisation holder of any defect that could result in a recall or an abnormal restriction on supply and, in so far as possible, indicate the countries of destination.
In plain words. The maker investigates every complaint about a defect, and tells the authority about any defect that could lead to a recall or a shortage.
The maker can recall products “promptly and at any time” (Article 13(1)), and evaluates its recall arrangements periodically, considering mock recalls (Chapter 8, 8.30).
What to do. Write the complaint and recall procedures, name who tells the competent authority about a defect, and test the recall arrangements.
Evidence to keep. Complaint records and investigations; recall records; the documented evaluation of the recall arrangements.
Self-inspection (Article 14, Chapter 9)
The manufacturer shall be required to conduct repeated self-inspections as part of the pharmaceutical quality system in order to monitor the implementation and respect of good manufacturing practice and to propose any necessary corrective measures and/or preventive actions. Records shall be maintained of such self-inspections and any corrective actions subsequently taken.
In plain words. The maker inspects itself regularly, and records what it finds and what it does about it.
Chapter 9 asks for self-inspections “in an independent and detailed way by designated competent person(s) from the company” (9.2).
What to do. Set a self-inspection programme that covers every area in Chapter 9, and track each corrective action until you close it.
Evidence to keep. Self-inspection reports with their observations and the actions taken (9.3).
Active substances and excipients (Directive 2001/83/EC, Article 46(f))
The authorisation holder verifies GMP at its active substance makers and distributors “by conducting audits at the manufacturing and distribution sites”, itself or through a contracted party. It decides through a formalised risk assessment which good manufacturing practice applies to each excipient (Article 46(f)). Part II of the guidelines covers active substances.
What to do. Audit each active substance maker and distributor, and keep a documented risk assessment for each excipient.
Evidence to keep. Audit reports; excipient risk assessments.
The UK: what the manufacturer’s licence requires and how the MHRA inspects
Directive 2003/94/EC, the Good Manufacturing Practice Directive for Great Britain, covers the same subjects as Directive (EU) 2017/1572, article for article (Articles 6 to 14). Schedule 2A changes its references to EU law and EU bodies into UK ones. A licence holder who imports complies with the GMP principles and guidelines “in so far as they are relevant to the import of medicinal products” (regulation 38(3)(a)).
Regulation 37 sets the same duties on active substances and excipients as EU law: audits of active substance makers and distributors, and a formalised risk assessment for each excipient (regulation 37(3) to (5)). Regulation 41(2) requires “at least one qualified person” at the licence holder’s disposal at all times. In Great Britain, that person is responsible for securing that each batch made there “has been manufactured and checked in accordance with these Regulations and the requirements of the UK marketing authorisation” (Schedule 7, paragraph 12(1)(a)), with documentary evidence kept for at least five years (paragraph 15). The MHRA’s GMP guidance lists the “Orange guide: rules and guidance for pharmaceutical manufacturers and distributors 2022” beside EudraLex Volume 4.
The same guidance sets out how the agency inspects:
You will be inspected when you apply for a manufacturer or wholesaler dealer licence and then periodically based on risk assessments. Overseas manufacturing sites are also inspected.
In plain words. The agency inspects a site before it grants a licence, then again as often as the site’s risk rating requires, and inspects sites abroad too.
- Before the inspection. A site completes a GMP compliance report, except before a triggered inspection.
- The findings. Inspectors grade each deficiency as critical, major or other. A critical deficiency “has produced or significantly risks producing a product which is harmful to humans or veterinary patients”.
- After the inspection. The site answers the post-inspection letter with its corrective actions and dates. The same guidance says: “If they accept it, you will receive a GMP or GDP certificate with your inspection report.”
What to do. Keep the GMP compliance report current, answer each post-inspection letter with corrective actions and dates, and send an interim update when the site changes.
Evidence to keep. The compliance report; each post-inspection letter and your response; the certificate and inspection report.
Dated GMP changes in the US and the EU, in one place
| Rule or guideline | What changed | Date |
|---|---|---|
| 21 CFR Part 211 and the new Part 213 | Medical gases, as 213.3(b)(12) defines them, moved from Part 211 to their own cGMP rule, Part 213, Current Good Manufacturing Practice for Medical Gases | Effective 18 December 2025 (final rule, 89 FR 51738) |
| EU GMP Annex 19, Reference and Retention Samples | Section 9 rewritten for parallel imported, distributed and traded products: a retention sample from each re-packaging operation, kept at least one year after expiry; a photographic or digital sample only where justified and agreed in advance with the competent authority | Has applied since 24 September 2026 (Commission document of 23 June 2026) |
| PIC/S PI 058-1, interpretation of the 2022 Annex 1 | Answers on the most important changes in Annex 1; it adds no GMP requirements | In force since 28 October 2026 |
| EU GMP Annex 1, Manufacture of Sterile Medicinal Products | Revision of the 2007 version | In operation since 25 August 2023; point 8.123 since 25 August 2024 |
| EU GMP Chapters 1 and 4, Annex 11, and a new Annex 22 on artificial intelligence | Drafts; the Commission’s consultations ran from 7 July to 7 October 2025 (Chapter 4, Annexes 11 and 22) and from 3 September to 3 December 2025 (Chapter 1, to reflect ICH Q9(R1) on quality risk management) | Not adopted by 19 November 2026; the Volume 4 page still lists Chapter 1 of 2013 and the January 2011 versions of Chapter 4 and Annex 11 |
The MHRA’s GMP guidance does not say whether the revised Annex 19 applies at GB sites; for Annex 1, see “Sterile products” above.
What to do. If you re-package parallel imports, keep a retention sample of the re-packaged product from each operation, and agree any photographic or digital sample with the competent authority first.
Evidence to keep. The retention sample log for each re-packaging operation; any written agreement for photographic samples.
What a GMP failure means in each market
The US: from a Form FDA 483 to a warning letter, import alert or court
At the end of an inspection, the investigators give the firm’s management a Form FDA 483 that lists what they observed. The agency’s draft guidance of March 2026 recommends a response “within 15 business days after the FDA 483 was issued”, and says the agency “will not ordinarily delay regulatory action, such as issuing a warning letter, to review a response to an FDA 483 that is received more than 15 business days after the FDA 483 was issued.” A warning letter “requests a response with a certain timeframe”, and the FDA publishes its warning letters on its website.
For products from abroad, the agency can place a product on an import alert and detain future shipments “without having to test or otherwise physically examine it”, and the Act refuses entry to an imported drug that appears to be adulterated (21 U.S.C. 381(a)). A breach makes the drug adulterated (210.1(b), quoted above). The agency explains that the word describes how the firm made the drug: “This kind of adulteration means that the drug was not manufactured under conditions that comply with CGMP.” What can follow includes a recall, seizure and injunction cases in court, and criminal cases “seeking fines and jail time”.
What to do. Answer each 483 observation in writing within 15 business days, with the corrective action, its owner and its date.
Evidence to keep. Each Form FDA 483, your response, and the records that show each action closed.
The EU: a finding in the Union database and action on the authorisation
After every inspection, the authority reports whether the site complies (Directive 2001/83/EC, Article 111(3)). A finding that it does not goes into the Union database (Article 111(7)). The authority can then act on the authorisation:
In addition to the measures specified in Article 117, the competent authority may suspend manufacture or imports of medicinal products coming from third countries, or suspend or revoke the manufacturing authorization for a category of preparations or all preparations where Articles 42, 46, 51 and 112 are not complied with.
In plain words. If a maker breaks its GMP duties, the authority can suspend or revoke its manufacturing authorisation, for some products or all of them.
The UK: action on the licence
Regulation 36(1) makes the GMP duty in regulation 37 a provision of the manufacturer’s licence. The licensing authority may suspend, revoke or vary a licence where “the holder of the licence has materially contravened a provision of it” (regulation 26(4)(c)). The MHRA’s guidance says that after critical deficiencies, or action plans left unresolved, its Inspection Action Group “can refuse or suspend your licence, increase inspection visits or request a meeting with the licence holder.”
How one quality system can serve the US, EU and UK markets
That core work, listed at the top of this guide, is also part of selling in each market. The FDA says: “The approval process for new and generic drug marketing applications includes a review of the manufacturer’s compliance with the CGMP.”
The agency’s mutual recognition agreements mean fewer repeat inspections:
Mutual Recognition Agreements (MRA) between FDA and foreign regulatory authorities allow drug inspectors to rely upon information from drug inspections conducted within each other’s borders.
In plain words. Regulators with an agreement can use each other’s inspection results, so a site need not face the same inspection twice.
The same page says the FDA has these agreements “in force with the European Union, Switzerland, and the United Kingdom”. In the EU, such an arrangement can relieve the qualified person of the controls on imported batches (Directive 2001/83/EC, Article 51(2)), and the revised Annex 19 lets the reference samples stay at the site of manufacture (7.2.1). Great Britain gives the same relief for countries on its approved country for batch testing list (Human Medicines Regulations 2012, Schedule 7, paragraph 14).
The same record may help a contract manufacturer win contracts. Chapter 7 makes each EU contract giver assess a contract acceptor before it outsources (7.5), and in the US the contract giver’s quality control unit approves or rejects what its contract maker produces (211.22(a)). An EU GMP certificate is in a public Union database that any contract giver can search.
What to do. Build one pharmaceutical quality system to Chapter 1 of the EU guidelines, then keep one list of each market’s own requirements, each mapped to the procedure that meets it. If you export between these markets, check whether a mutual recognition agreement covers your products.
Evidence to keep. That list, with the source of each requirement; the GMP certificates and inspection reports from each authority.
Questions about GMP and cGMP
What is GMP?
GMP stands for good manufacturing practice. Directive (EU) 2017/1572 defines it as “the part of the quality assurance which ensures that medicinal products are consistently produced, imported and controlled in accordance with the quality standards appropriate to their intended use.” The MHRA calls it “the minimum standard that a medicines manufacturer must meet in their production processes.”
What is the difference between GMP and cGMP?
cGMP is the FDA’s name for good manufacturing practice. The agency says “the ‘C’ in CGMP stands for ‘current,’ requiring companies to use technologies and systems that are up-to-date in order to comply with the regulations.” EU and UK law use the term GMP.
What are 21 CFR Parts 210 and 211?
They are the FDA’s minimum cGMP regulations for drugs. Part 210 says what the rules cover and that a drug made in breach of them is adulterated. Part 211 sets the cGMP for finished pharmaceuticals in eleven subparts, from general provisions to returned and salvaged drug products.
Is there a GMP certificate?
In the EU, yes: within 90 days of an inspection that finds a site compliant, the authority issues a certificate of good manufacturing practice and enters it in a Union database open to the public (Directive 2001/83/EC, Article 111(5) and (6)), which the EMA runs as the EudraGMDP database. The MHRA issues a GMP certificate with its inspection report once it accepts the site’s response. Parts 210 and 211 provide for no certificate, but for exported drugs the FDA issues certificates of pharmaceutical product, which give “information about the drug’s U.S. marketing status and the manufacturer’s compliance with FDA’s requirements”, and CGMP declarations, letters to foreign regulators “that convey CGMP compliance status of establishments FDA has inspected.”
What is EU GMP Annex 1?
Annex 1 of the EU GMP guidelines covers the manufacture of sterile medicinal products. Its current version came into operation on 25 August 2023, and its point 8.123 on 25 August 2024. It asks for a contamination control strategy, four grades of cleanroom, environmental and process monitoring, and aseptic process simulations, normally twice a year.
What is the difference between GMP and GDP?
GMP covers how medicines are made and controlled. The MHRA says: “Good distribution practice (GDP) requires that medicines are obtained from the licensed supply chain and are consistently stored, transported and handled under suitable conditions, as required by the MA or product specification.” EU law asks authorisation holders to use active substances made to GMP and distributed to GDP (Directive 2001/83/EC, Article 46(f)).
More guides
- 21 CFR Part 11 · EU Annex 1121 CFR Part 11 compliance: the requirements and EU Annex 11 comparedRead the guide
- 21 CFR Part 806 · EU MDR · UK MDR 2002Field safety corrective action and medical device recalls: the US, EU and UK rulesRead the guide
- 21 CFR Part 860 · EU MDR Annex VIIIMedical device classification: class 1, 2 and 3 under the FDA, EU and MHRA rulesRead the guide
Sources
United States
- 21 CFR Parts 210, 211 and 213, eCFR, up to date as of 17 November 2026: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211
- 21 CFR 11.1: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11/subpart-A/section-11.1
- 21 U.S.C. 321, the Act’s definition of a drug, govinfo: https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapII-sec321.htm
- 21 U.S.C. 351, adulterated drugs, govinfo: https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec351.htm
- 21 U.S.C. 381, imports, govinfo: https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapVIII-sec381.htm
- Federal Register, the medical gases final rule, 89 FR 51738, 18 June 2024: https://www.federalregister.gov/documents/2024/06/18/2024-13190/current-good-manufacturing-practice-certification-postmarketing-safety-reporting-and-labeling
- FDA, Inspection Observations, with its fiscal year 2025 data set: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
- FDA, Form 483 Frequently Asked Questions: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
- FDA, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection, draft guidance, March 2026: https://www.fda.gov/media/191427/download
- FDA, About Warning and Close-Out Letters: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters
- FDA, Import Alerts: https://www.fda.gov/industry/actions-enforcement/import-alerts
- FDA, Facts About the Current Good Manufacturing Practice (CGMP): https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp
- FDA, Current Good Manufacturing Practice (CGMP) Regulations: https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
- FDA, Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients-guidance-industry
- FDA, Electronic Certificates of Pharmaceutical Product: https://www.fda.gov/drugs/human-drug-exports/electronic-certificates-pharmaceutical-product
- FDA, Current Good Manufacturing Practice Declarations: https://www.fda.gov/drugs/human-drug-exports/current-good-manufacturing-practice-declarations
- FDA, Mutual Recognition Agreements (MRA): https://www.fda.gov/international-programs/international-arrangements/mutual-recognition-agreements-mra
- FDA, Quality Management System Regulation (QMSR): https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
European Union
- Commission Directive (EU) 2017/1572, EUR-Lex: https://eur-lex.europa.eu/eli/dir/2017/1572/oj/eng
- Directive 2001/83/EC, consolidated text of 1 January 2025, EUR-Lex: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083-20250101
- European Commission, EudraLex Volume 4, Good Manufacturing Practice guidelines (Chapters 1 to 9 and the annexes): https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en
- European Commission, Annex 1, Manufacture of Sterile Medicinal Products: https://health.ec.europa.eu/document/download/e05af55b-38e9-42bf-8495-194bbf0b9262_en?filename=20220825_gmp-an1_en_0.pdf
- European Commission, Annex 19, Reference and Retention Samples, C(2026) 4135, 23 June 2026: https://health.ec.europa.eu/document/download/831d392e-bcc4-4552-8011-2b724b8655de_en?filename=c2026-4135_en_act_en.pdf
- European Commission, consultation on Chapter 4, Annex 11 and new Annex 22: https://health.ec.europa.eu/consultations/stakeholders-consultation-eudralex-volume-4-good-manufacturing-practice-guidelines-chapter-4-annex_en
- European Commission, consultation on Chapter 1: https://health.ec.europa.eu/consultations/stakeholders-consultation-eudralex-volume-4-good-manufacturing-practice-guidelines-chapter-1_en
- EMA, EudraGMDP database: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/compliance-research-development/good-manufacturing-practice/eudragmdp-database
United Kingdom
- The Human Medicines Regulations 2012 (SI 2012/1916), regulations 8, 17, 26, 36, 37, 38, 41, B17 and C17, and Schedules 2A and 7, legislation.gov.uk: https://www.legislation.gov.uk/uksi/2012/1916/contents
- Directive 2003/94/EC, legislation.gov.uk: https://www.legislation.gov.uk/eudr/2003/94/contents
- European Union (Withdrawal Agreement) Act 2020, section 39 (IP completion day), legislation.gov.uk: https://www.legislation.gov.uk/ukpga/2020/1/section/39
- MHRA, Medicines: good manufacturing practice and good distribution practice: https://www.gov.uk/guidance/good-manufacturing-practice-and-good-distribution-practice
- MHRA, Good manufacturing practice inspection deficiencies (2019 data): https://www.gov.uk/government/statistics/good-manufacturing-practice-inspection-deficiencies
- MHRA, Clinical trials for medicines: good manufacturing practice and radiopharmaceutical investigational medicinal products: https://www.gov.uk/guidance/clinical-trials-for-medicines-good-manufacturing-practice-and-radiopharmaceutical-investigational-medicinal-products
- MHRA Inspectorate blog, Understanding Annex 1: A Harmonised Approach to Interpretation, 16 November 2026: https://mhrainspectorate.blog.gov.uk/2026/11/16/understanding-annex-1-a-harmonised-approach-to-interpretation/
General information, not legal advice. We read every source above in November 2026 and check them each month; the date at the top of the page shows the last review.